What are the reasons for not frequently using bevacizumab? (Please select all that apply) (Presented for each tumor type and treatment setting where respondents cited they "Not so often/occasionally for certain patients (10%-24% of cases)," "Rarely (<10% of cases)," or "Never" prescribe bevacizumab.).
A. Patient clinical factors (i.e., age, performance status, comorbidities, contraindications, etc.) B. I do not consider bevacizumab to be the optimal treatment option in this tumor type overall C. Not convinced of bevacizumab's efficacy in this setting/tumor type D. Not convinced of bevacizumab's safety in this setting/tumor type E. Access-related issues including reimbursement, high out-of-pocket cost to the patient, availability where I practice; guidelines-regulatory authorities have not approved use in this setting F. Other (please specify)
On an overall basis, how do you find access (i.e., reimbursement, high out-of-pocket costs to the patient, availability where you practice; and guidelines/regulatory authorities have not approved use in this setting) to bevacizumab for patients with mCRC, mNSCLC, mOC, mBC, and GBM?
Not at All Easy Very Easy 1 2 3 4 5 6 7
Which of the following make access to bevacizumab challenging in this particular tumor type? (Please select all that apply) (Presented for each tumor type in which ease of access was considered difficult (responses ≤3). GBM, glioblastoma multiforme; mBC, metastatic breast cancer; mCRC, metastatic colorectal cancer; mNSCLC, metastatic non-squamous non-small-cell lung cancer; mOC, metastatic ovarian cancer).
A. Not reimbursed/covered by healthcare system and/or patients' private insurance B. Not available for use in the hospital/clinic where I practice C. Use in this tumor type/setting is not recommended by treatment guidelines/protocol I follow D. Use in this tumor type/setting is not approved by regulatory authorities E. High out-of-pocket treatment costs for patient Figure S1 . Reasons for not frequently prescribing bevacizumab, by primary tumor type and line of therapy a . (A) mCRC, (B) EGFR WT or unknown mNSCLC, (C) EGFR Mut mNSCLC, (D) mOC, (E) mBC, and (F) GBM. A,B,C Letters indicate a significant difference between subgroups (p < 0.05): A = US; B = EU; C = EM. a Percentages based on respondents who reported not frequently prescribing bevacizumab (a score ≥3 on a scale from 1 = always to 5 = never). b Small sample size; results interpreted with caution. mCRC, metastatic colorectal cancer; EGFR, epidermal growth factor receptor; WT, wild-type; mNSCLC, metastatic non-squamous non-small-cell lung cancer; Mut, mutant; mOC, metastatic ovarian cancer; mBC, metastatic breast cancer; GBM, glioblastoma; EU, European Union (United Kingdom (UK), Italy, Germany, and France); EM, emerging markets (Brazil, Mexico, and Turkey); KRAS, Kirsten rat sarcoma viral oncogene homolog. 
